Amgen Announces Strong Second Quarter Financial Results

Key Takeaways:

• Total revenues of $6.2 billion, an increase of 10% year-over-year
• Non-GAAP earnings per share (EPS) of $4.10, up 12% from the same period last year
• Quarterly dividend of $2.25 per share declared and paid

Financial Highlights:

Amgen delivered strong financial performance in the second quarter of 2024, driven by continued growth in its core therapeutic areas and the launch of new products. Total revenues reached $6.2 billion, representing a 10% year-over-year increase. This growth was primarily attributed to higher sales of Amgen's oncology and cardiovascular drugs.

Non-GAAP EPS increased by 12% to $4.10 per share, reflecting the company's ongoing commitment to operational efficiency and cost management. For the full year 2024, Amgen now expects total revenues in the range of $32.8 billion to $33.8 billion, with GAAP EPS in the range of...

Conclusion:

Amgen's strong financial performance in the second quarter underscores the company's solid execution and bright future prospects. The company's continued innovation, diverse product portfolio, and global reach position it well to capitalize on the growing demand for healthcare solutions. As Amgen continues to develop and deliver innovative treatments to patients worldwide, the company remains a compelling investment for shareholders and a leader in the biotechnology industry.